|Other Names||Ribose-phosphate pyrophosphokinase 1, PPRibP, Phosphoribosyl pyrophosphate synthase I, PRS-I, PRPS1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7178a was selected from the C-term region of human PRPS1/2/3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Phosphoribosylpyrophosphate synthetase (PRPS) catalyzes the phosphoribosylation of ribose 5-phosphate to 5-phosphoribosyl-1-pyrophosphate, which is necessary for the de novo and salvage pathways of purine, pyrimidine, and pyridine biosynthesis. Defects in PRPS1 are the cause of PRPS-related gout, also known as gout due to PRPS1 superactivity. It is a familial disorder characterized by excessive purine production, gout and uric acid urolithiasis.
Ahmed, M., et al., J. Biol. Chem. 274(11):7482-7488 (1999).Ishijima, S., et al., Biochim. Biophys. Acta 1342(1):28-36 (1997).Becker, M.A., et al., J. Biol. Chem. 271(33):19894-19899 (1996).Roessler, B.J., et al., J. Biol. Chem. 268(35):26476-26481 (1993).Ishizuka, T., et al., Biochim. Biophys. Acta 1130(2):139-148 (1992).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.